Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist, which is indicated for type 2 diabetes mellitus and weight management. It is sold under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management and weight loss. Wegovy is also indicated to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease, obesity or overweight. Semaglutide was first approved for use in humans by the FDA in 2017. In type 2 diabetes: Incretins, such as GLP-1, enhance glucose-dependent insulin secretion by pancreatic beta-cells, suppress inappropriately elevated glucagon secretion, and slows the gastric emptying. This decreases blood sugar levels. In weight management: GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. Common adverse effects include; nausea, hypoglycaemia, diarrhoea, abdominal pain, headache, fatigue and constipation among many others. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia type 2. Sources: https://reference.medscape.com/drug/ozempic-rybelsus-wegovy-semaglutide-1000174#10 https://en.m.wikipedia.org/wiki/Semaglutide #fip #fipecpg #knowyourmedicines #pharmacy #semaglutide #think_health #think_pharmacy Interested in becoming an ECPG member? Find out more here: https://www.fip.org/about-early-career-pharmaceutical-group Follow our WhatsApp channel on: https://whatsapp.com/channel/0029VafVnPqIHphGbcLJLG2U